ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,043
0,00%
Bitcoin
96.429,46
-0,80%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Xeris Biopharma Holdings Inc (XERS)

  7. Xeris Biopharma Holdings Inc (XERS) News

XERS

Xeris Biopharma (XERS)

Xeris Biopharma Holdings Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:XERS
DatumZeitQuelleÜberschriftSymbolFirma
26/11/202413h00Business WireXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202413h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
08/11/202413h00Business WireXeris Biopharma Reports Third Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
31/10/202413h00Business WireXeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
04/10/202422h05Business WireXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
22/08/202413h00Business WireXeris to Participate in Upcoming Investor ConferencesNASDAQ:XERSXeris Biopharma Holdings Inc
09/08/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202422h27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
08/08/202413h00Business WireXeris Biopharma Reports Second Quarter 2024 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
02/08/202423h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
02/08/202423h16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
02/08/202422h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
25/07/202413h00Business WireXeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
08/07/202413h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
08/07/202413h00Business WireXeris Biopharma Announces CEO Succession PlanNASDAQ:XERSXeris Biopharma Holdings Inc
03/07/202419h05Business WireXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
05/06/202422h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
05/06/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
03/06/202413h00Business WireXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202413h30Business WireXeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)NASDAQ:XERSXeris Biopharma Holdings Inc
30/05/202413h00Business WireXeris to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
09/05/202413h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
09/05/202413h00Business WireXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/05/202413h00Business WireXeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsNASDAQ:XERSXeris Biopharma Holdings Inc
02/05/202413h00Business WireXeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
03/04/202422h05Business WireXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
02/04/202413h00Business WireXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202422h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XERSXeris Biopharma Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:XERS

Kürzlich von Ihnen besucht

NYSE
BBLU
EA Series Trust
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten